While SGLT2 inhibitors are well established in the treatment of type 2 diabetes, heart failure and chronic kidney disease, their role in the primary prevention of metabolic dysfunction is unclear. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.